Bayer Pharma has gained the right to use ChromoTek’s Cell Cycle Chromobody® technology for drug profiling by high-content analysis. Bayer will apply Chromobody technology for real-time monitoring of cell cycle progression in drug discovery.
ChromoTek’s Chromobody technology is a universal live-cell imaging technology for high-content analysis. Chromobodies are single-domain antibodies that have been genetically fused to fluorescent proteins to serve as functional nanoprobes in living cells. The Chromobody technology allows users to trace endogenous intracellular antigens and to visualize dynamic changes of these targets within living cells.
ChromoTek says that currently available Chromobodies trace cellular processes like cell cycle, apoptosis, DNA damage and repair, or allow cytoskeletal analysis. The Cell Cycle Chromobody cell line licensed by Bayer traces the complete cell cycle in real time in live cells in a noninvasive manner while providing full flexibility to multiplex with other procedures, the firm reports.
